⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596390 | 0.85 | GLO1 (0.39) | — | |
| SCHEMBL4676104 | 0.83 | — | — | |
| SCHEMBL8185907 | 0.79 | — | — | |
| SCHEMBL285496 | 0.79 | — | — | |
| SCHEMBL2178036 | 0.78 | ALDH1A1 (0.46) | — | |
| SCHEMBL14010247 | 0.77 | GLO1 (0.31) | — | |
| SCHEMBL110228 | 0.77 | — | — | |
| SCHEMBL3012356 | 0.76 | TSHR (0.43) | — | |
| Methane SCHEMBL29017329 | 0.74 | — | — | |
| SCHEMBL14431639 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076935-A1 | PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2026-03-19 | — | — | US | disclosed |
| EP-4683625-A2 | PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE | The Trustees Of Columbia University In The City Of New York (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025058667-A2 | PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-03-20 | — | — | WO | disclosed |
| EP-4329743-A1 | PYRUVATE ESTERS FOR THE TREATMENT OF VIRAL DISEASES | Birkenmeier, Gerd (DE) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022228651-A1 | PYRUVATE ESTERS FOR THE TREATMENT OF VIRAL DISEASES | BIRKENMEIER GERD (DE) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022228652-A1 | MEANS AND METHOD FOR TREATING VIRAL INFECTIONS | BIRKENMEIER GERD (DE) | 2022-11-03 | — | — | WO | disclosed |
| US-20170335653-A1 | METHOD OF EXTRACTING UNDERGROUND RESOURCES AND HYDROLYSIS-BLOCKING AGENT FOR USE IN THE METHOD | TOYO SEIKAN GROUP HOLDINGS, LTD. (JP) | 2017-11-23 | — | — | US | disclosed |
| EP-2493467-B1 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS | HILLS PET NUTRITION INC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2519115-B1 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF | HILLS PET NUTRITION INC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20170002135-A1 | POLYOXALATES AND A PROCESS FOR THE PRODUCTION THEREOF | TOYO SEIKAN GROUP HOLDINGS, LTD. (JP) | 2017-01-05 | — | — | US | disclosed |
| EP-1877141-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA | Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH (DE) | 2008-01-16 | — | — | EP | disclosed |
| EP-1874407-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108682-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108679-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE TO COMBAT CANCER | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108680-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST PROTOZOA AND HELMINTHES | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108681-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| EP-1494659-B1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS INC (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1494659-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | Critical Therapeutics, Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20030232884-A1 | New pharmaceutical formulation | CRITICAL THERAPEUTICS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003088955-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMINE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |